Peer-influenced content. Sources you trust. No registration required. This is HCN.

Journal of Clinical OncologySix-Year Results From RELEVANCE: Lenalidomide Plus Rituximab (R2) Versus Rituximab-Chemotherapy Followed by Rituximab Maintenance in Untreated Advanced Follicular Lymphoma

In patients with advanced-stage, untreated follicular lymphoma (FL), the RELEVANCE trial demonstrated that rituximab plus chemotherapy (R-chemo) and lenalidomide plus rituximab (R2) had comparable efficacy (FL). After six years of follow-up, a report on the second interim analysis of the RELEVANCE experiment is presented here.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form